Amylyx Pharmaceuticals

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. Founded in 2013 by Joshua Cohen, Justin Klee, and Kent Leslie, the company focuses on developing innovative therapies for neurodegenerative diseases and other challenging medical conditions. Their mission is to address significant unmet medical needs through rigorous scientific research and a deep understanding of the communities they serve. The company is advancing several investigational therapies, including Avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism, AMX0035 for Wolfram syndrome and progressive supranuclear palsy, and AMX0114 for amyotrophic lateral sclerosis. Amylyx collaborates closely with the ALS community and various stakeholders in the medical field to enhance its research and development efforts. With a commitment to innovation and improving patient outcomes, Amylyx Pharmaceuticals is expanding its global presence, including a recent establishment of a subsidiary in Japan.